A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

被引：12

作者：

Blum, Kristie A.

Christian, Beth ^{[1
]}

Flynn, Joseph M. ^{[1
]}

Jaglowski, Samantha M. ^{[2
]}

Jones, Jeffrey Alan ^{[3
]}

Maddocks, Kami

Byrd, John C.

机构：

[1] Ohio State Univ, James Graham Brown Canc Ctr, Columbus, OH 43210 USA

[2] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

[3] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.1643.1643

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1643

引用

页数：2